{
    "title": "109_s2255",
    "content": "The Act titled \"Medicare Drug Formulary Protection Act\" allows for the removal of covered Part D drugs from the prescription drug plan formulary. The Medicare Drug Formulary Protection Act allows the PDP sponsor of a prescription drug plan to impose restrictions on coverage starting in 2006. Starting in 2006, the PDP sponsor of a prescription drug plan cannot remove a covered part D drug from the plan formulary or impose restrictions on its coverage. Starting in 2006, a PDP sponsor cannot remove a covered part D drug from the plan formulary or impose restrictions on its coverage, except as permitted by the Secretary for new considerations. Starting in 2006, a PDP sponsor cannot impose restrictions on covered part D drugs, except as permitted by the Secretary for new considerations. The PDP sponsor of a prescription drug plan cannot remove a covered part D drug or impose restrictions for newly enrolled individuals. The PDP sponsor of a prescription drug plan cannot remove a covered part D drug or impose restrictions on coverage for newly enrolled individuals after the date of enactment. The PDP sponsor cannot impose restrictions on drug coverage for new enrollees, except as permitted by the Secretary until December 31 of the following plan year. The PDP sponsor cannot impose restrictions on drug coverage for new enrollees from enrollment date to December 31 of the following plan year, unless permitted by the Secretary for new therapeutic uses and newly covered part D drugs. The PDP sponsor cannot restrict drug coverage for new enrollees unless approved by the Secretary for new therapeutic uses and newly covered part D drugs, with exceptions for brand name drugs with generic alternatives available. The PDP sponsor cannot restrict drug coverage for new enrollees unless approved by the Secretary for new therapeutic uses and newly covered part D drugs, with exceptions for brand name drugs with generic alternatives available, which includes generic drugs approved under section 505(j) of the Food and Drug Cosmetic Act and brand name drugs that go off-patent during the specified period. The PDP sponsor cannot restrict drug coverage for new enrollees unless approved by the Secretary for new therapeutic uses and newly covered part D drugs. Restrictions may apply if the drug is a brand name drug going off-patent, subject to a clinical warning, or determined to be. The Commissioner of Food and Drugs issues a clinical warning that imposes a restriction or limitation on the drug, or if the drug has been determined to be ineffective. The PDP sponsor of a prescription drug plan must provide notice of any removal or change under the exception to the limitation. The PDP sponsor of a prescription drug plan must provide notice of any removal or change under the exception to the limitation for a change in formulary or other restrictions on coverage. Each PDP sponsor offering a prescription drug plan must provide annual notice of changes in formulary and coverage restrictions to enrollees during the coordinated election period. Each PDP sponsor offering a prescription drug plan must provide annual notice of changes in formulary or coverage restrictions to enrollees during the coordinated election period. The notice should detail any changes in coverage for the upcoming plan year. The PDP sponsor must notify enrollees of any changes in formulary or coverage restrictions for the upcoming plan year, with the amendment applying to annual coordinated election periods after the enactment of the Act."
}